Publicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (4)

2023

  1. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

    Nature communications, Vol. 14, Núm. 1, pp. 1359

2022

  1. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5

  2. Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

    Neuro-Oncology Advances, Vol. 4, Núm. 1

2020

  1. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

    Annals of Oncology, Vol. 31, Núm. 6, pp. 780-788